Information Provided By: 
Fly News Breaks for September 6, 2018
ACAD
Sep 6, 2018 | 07:45 EDT
After hosting a dinner with management, JPMorgan analyst Cory Kasimov is "incrementally more confident" in Nuplazid's near term commercial outlook in parkinson's disease psychosis. Management is confident that there is no safety issue with Nuplazid based on both post-marketing pharmacovigilance and clinical data, Kasimov tells investors in a research note. The analyst views Acadia's risk/reward "as interesting" at current share levels. He keeps an Overweight rating on the name.
News For ACAD From the Last 2 Days
